COSCIENS Biopharma P/E Ratio

COSCIENS Biopharma (CSCI) currently reports a P/E ratio of -0.4. That is below the sector sector average of 33.83. Use the charts on this page to explore COSCIENS Biopharma's P/E ratio history and peer comparisons.

COSCIENS Biopharma's P/E ratio of -0.4 is lower than the its sector sector average of 33.83. That is roughly 101.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates COSCIENS Biopharma's market price to a fundamental measure such as earnings, sales, or book value. At -0.4, CSCI can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.4, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 33.83. From there, open related valuation or income-statement pages for COSCIENS Biopharma, and consider following CSCI for alerts when major investors trade the stock.